In a landmark decision aimed at enhancing access to cutting-edge medical treatments, the Indian government has announced a significant policy shift. The new directive, issued via an executive order, eliminates the requirement for local clinical trials for drugs and vaccines that have already been approved by stringent regulatory agencies in the United States, United Kingdom, Japan, Australia, Canada, and the European Union. This change will allow these advanced therapies to enter the Indian market directly, provided they receive approval from the Central Drugs Standard Control Organization (CDSCO), India’s primary drug regulatory authority.

The policy change was driven by the need to prevent delays in making critical medications available to patients in India. Previously, new drugs approved in major international markets often faced delays in India due to the requirement for local clinical trials, which could not always be conducted or completed in a timely manner. By removing this barrier, the government aims to facilitate faster access to innovative treatments.

A senior official from the Health Ministry emphasized that the differences between populations typically affect only a small percentage—around 0.1% to 0.2%—thus reducing the necessity for local trials in many cases. This policy is expected to significantly speed up the introduction of breakthrough therapies, including Chimeric Antigen Receptor (CAR) T-cell therapy for leukemia and Sacituzumab govitecan for advanced breast cancer, both of which represent significant advancements in treatment options.

Dr. Pooja Sharma, project lead at Patient Advocates for Clinical Research (PACER), noted that while the requirement for local trials is waived, the CDSCO will maintain rigorous post-marketing surveillance and conduct clinical trials to monitor the performance and safety of these drugs within the Indian context. This approach ensures that the expedited access to essential therapies does not compromise safety and efficacy standards.

Overall, this policy change is expected to greatly benefit Indian patients by providing quicker access to essential and advanced treatments while ensuring that the regulatory framework remains robust and protective of public health.

Also Read : India's Civil Aviation Minister Outlines Strategies to Boost MRO Sector to $4 Billion by 2031

Check latest IPO Review & analysis, Live GMP today, Live Subscription Status Today, Share Price, Financial Information, latest IPO news, Upcoming IPO News before applying in the IPO. The Upcoming IPOs in this week and coming weeks are Utssav Cz Gold Jewels Limited, Dhariwalcorp Limited, Ola Electric Mobility Limited, Ceigall India Limited, Afcom Holdings Limited, Picture Post Studios Limited IPO.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst & Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX & Upstox.